Uncategorized
Ocata receives EMA guidelines for Stargardt macular degeneration trial
Ocata Therapeutics received written formal guidance from the European Medicines Agency to initiate a clinical trial for its Stargardt macular degeneration program, according to a press release.The company intends on enrolling approximately 100 patients in the trial and including an untreated control arm based on guidance from the FDA.